Compare
Provectus Biopharmaceuticals, Inc. vs Vyome Holdings, Inc vs Abvc Biopharma, Inc. vs Can-Fite BioPharma Ltd.
| Latest fiscal year | Provectus Biopharmaceuticals, Inc. PVCT | Vyome Holdings, Inc HIND | Abvc Biopharma, Inc. ABVC | Can-Fite BioPharma Ltd. CANF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $336.1K | $319.7K | $296.0K | $405.0K |
| Revenue growth (YoY) | -45.5% | +24.4% | -41.9% | -39.9% |
| Gross margin | n/a | 68.4% | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$5.43M | -$10.26M | -$7.91M | -$9.83M |
| EPS (Diluted) | -$0.01 | -$4.86 | -$0.39 | -$5.97 |
| Operating cash flow | -$3.33M | -$3.75M | -$2.99M | -$8.95M |
| Free cash flow | n/a | n/a | n/a | -$8.95M |
| Cash & equivalents | $251.3K | $4.98M | $681.5K | $5.53M |
| Total assets | $697.5K | $6.50M | $21.06M | $9.51M |
| Total liabilities | $7.00M | $2.74M | $7.76M | n/a |
| Shareholders' equity | -$6.30M | $3.76M | $11.11M | $5.59M |
| Return on year-end equity | n/a | -272.8% | -71.2% | -175.8% |
| Shares outstanding | 420.28M | 5.92M | 25.05M | 2.62M |
Revenue, most recent five fiscal years
| Fiscal year | Provectus Biopharmaceuticals, Inc. | Vyome Holdings, Inc | Abvc Biopharma, Inc. | Can-Fite BioPharma Ltd. |
|---|---|---|---|---|
| Latest | $336.1K Ended 2025-12-31 | $319.7K Ended 2025-12-31 | $296.0K Ended 2025-12-31 | $405.0K Ended 2025-12-31 |
| 1 year earlier | $617.1K Ended 2024-12-31 | $256.9K Ended 2024-12-31 | $509.6K Ended 2024-12-31 | $674.0K Ended 2024-12-31 |
| 2 years earlier | $557.7K Ended 2023-12-31 | $8.68M Ended 2023-12-31 | n/a | $743.0K Ended 2023-12-31 |
| 3 years earlier | $989.0K Ended 2022-12-31 | $11.24M Ended 2022-12-31 | n/a | $810.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $13.60M Ended 2021-12-31 | n/a | $853.0K Ended 2021-12-31 |